SenesTech competitors

Robert was appointed President and Chief Executive Officer of Cytokinetics in January 2007 and has been a member of our Board of Directors since then. Previously, he served as Cytokinetics’ President and held other senior-level positions at the Company overseeing research and development, finance, corporate development, legal, commercial operations, and business development at various times since participating in the launch of Company operations in 1998. Prior to Cytokinetics, Robert held senior positions in business development and marketing at COR Therapeutics from 1991 to 1998. He also performed roles of increasing responsibility in sales, marketing, and other pharmaceutical business functions at Marion Laboratories and Syntex Corporation beginning in 1981. Robert has served on the faculty at the Center for BioEntrepreneurship at University of California, San Francisco, where he taught a corporate finance course to graduate students. He co-chaired the BIO Business Development Committee and is a frequent lecturer on matters of business development and finance in the biopharmaceutical industry. He served on the National Board of the American Committee of the Weizmann Institute of Science and established the Blum Family Venture Philanthropy Fund to propel basic science discoveries at the Institute with potential to benefit the Israeli life sciences economy. In addition, he established the Tikkun Olam Youth Science Prizes for Bay Area middle and high schools, designed to further science education and exploration in the spirit of repairing the world. Robert served on the Board of the Jewish Community Federation of San Francisco and founded and chaired its Business Leadership Council. He also served on the Boards of San Francisco’s Contemporary Jewish Museum and the Anti-Defamation League. Robert was named a Henry Crown Fellow of the Aspen Institute in recognition of his leadership in corporate and civic responsibilities. He is a member of the Aspen Global Leadership Network and has moderated seminars related to science, health, and technology at Aspen Action Forums. Mr. Blum received B.A. degrees in Human Biology and Economics from Stanford University and an M.B.A. from Harvard Business School. Robert was a fan of mountain bluegrass music long before it was fashionable and has been known to carry a harmonica in his briefcase, much to the dismay of nearby hotel guests. He enjoys trying to keep up with his wife Dana and daughters, Brittany and Bridget, as well as his Bernese mountain dog, Baron, on long hikes in the Presidio.

Enrique Conterno joined FibroGen as CEO in 2020. Enrique Conterno is a senior vice president of Eli Lilly and Company and president of Lilly Diabetes. Enrique joined Lilly in 1992 and has held a range of roles in sales, finance, marketing, business development, and general management. He served as marketing and sales director for Lilly’s Peru and Brazil affiliates, as executive marketing director for the intercontinental region and Japan, and as general manager for Lilly Mexico. Enrique was vice president of the company’s U.S. neuroscience business unit and vice president for health care professional markets. He served as president of Lilly’s U.S. affiliate until he was named president of Lilly Diabetes in 2009. Enrique earned a bachelor’s degree in mechanical engineering from Case Western Reserve University and a master’s degree in business administration from Duke University. He serves on the board of the National Association of Manufacturers (NAM) and as treasurer for the Board of Directors of the Indy Chamber of Commerce. He is also on the Board of Visitors for Duke’s Fuqua School of Business.

John Adent is a Board Member at NEOGEN CORP and President/CEO at NEOGEN CORP and is based in Lansing, Michigan. He has worked as Chief Executive Officer at ANIMAL HEALTH HOLDINGS, INC. and Pres & CEO:Animal Health at PATTERSON COMPANIES, INC.. John studied at DEPAUW UNIVERSITY between 1986 and 1990.

Rick Winningham has served as a member of our Board of Directors since May 2010. Since 2001, he has served as the Chief Executive Officer and a member of the Board of Directors of Theravance, Inc., a biopharmaceutical company, and in April 2010, he was appointed Chairman of the Board of Directors. From 1997 to 2001, he served as President of Bristol-Myers Squibb Oncology/Immunology/Oncology Therapeutics Network and, from 2000 to 2001, as President of Global Marketing. He is a member of the board of directors of the California Healthcare Institute (CHI) and is also a member of the External Advisory Board for the College of Business and Administration and Business Hall of Fame at Southern Illinois University.Rick Winningham holds an M.B.A. from Texas Christian University and a B.S. from Southern Illinois University.

Ron Squarer serves as Chairman and Executive Advisor at ADC Therapeutics SA (NYSE: ADCT) and directly supported the May 2020 company IPO. Mr. Squarer served as Chief Executive Officer and a member of the Array Biopharma Board of Directors from April 2012 through August 2019 when Pfizer Inc. acquired the company for $11.8 billion following the successful launch of the cancer treatments Braftovi® and Mektovi®. During his tenure, the company’s valuation grew ~40-fold through execution across research, development, and commercialization focused in the Oncology area. Array Biopharma’s research team is recognized for having invented Vitrakvi®/larotrectinib/TRK, Koselugo®/selumetinib/MEK, Tukysa®/tucatinib/HER2, ipatasertib/AKT, selpercatinib/RET, and MRTX849/KRAS-G12C among other molecules. Mr. Squarer has extensive commercial, development, research prioritization, and executive leadership expertise from a career spanning more than two decades in the biopharmaceutical industry. Before joining Array, Mr. Squarer held positions of increasing responsibility with Hospira, Inc., a global pharmaceutical and medical device company. In his last role there, as Senior Vice President and Chief Commercial Officer, he was responsible for delivering $4 billion in annual revenue. Mr. Squarer joined Hospira from Mayne Pharma, where he served as Senior Vice President, Global Corporate and Business Development when Mayne was sold to Hospira in 2007 for over $2 billion. Before Mayne Pharma, Mr. Squarer held leadership roles at both Pfizer, Inc. (including in Oncology), and SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) in the U.S. and Europe and currently serves as a member of the Board of Directors of Deciphera Inc. (NASDAQ: DCPH) and Travere Therapeutics Inc. (NASDAQ: TVTX) Mr. Squarer earned an MBA from the Kellogg School of Management, Northwestern University, and a bachelor’s degree in biochemistry from the University of California, Berkeley.

Highly motivated senior executive with general management experience in both large multi-national companies and small private equity environments in the diagnostic, medical device, pharmaceutical and life science industries. Demonstrated performance excellence in multi-disciplinary leadership roles including operations, marketing, sales, strategic planning, acquisitions and integrations on domestic and international level. Excel at turning around underperforming businesses with a combination of strong business acumen, outstanding leadership, customer relationships, and superior commercial execution. Dynamic leader with ability to build high performing teams and cross functional collaboration, align and inspire organizations towards a clear vision, and execute for sustainable results.